168 related articles for article (PubMed ID: 16087915)
1. Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis.
Ekstein D; Linetsky E; Abramsky O; Karussis D
Neurology; 2005 Aug; 65(3):456-8. PubMed ID: 16087915
[TBL] [Abstract][Full Text] [Related]
2. Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers.
Richez C; Blanco P; Lagueny A; Schaeverbeke T; Dehais J
Neurology; 2005 Apr; 64(8):1468-70. PubMed ID: 15851749
[TBL] [Abstract][Full Text] [Related]
3. Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis.
Kieseier BC; Hartung HP
Neurology; 2006 Mar; 66(6):955; author reply 955. PubMed ID: 16567732
[No Abstract] [Full Text] [Related]
4. Urtica ferox neuropathy.
Hammond-Tooke GD; Taylor P; Punchihewa S; Beasley M
Muscle Nerve; 2007 Jun; 35(6):804-7. PubMed ID: 17206658
[TBL] [Abstract][Full Text] [Related]
5. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
Zwibel HL;
Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
[TBL] [Abstract][Full Text] [Related]
6. Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.
Strueby L; Nair B; Kirk A; Taylor-Gjevre RM
Scand J Rheumatol; 2005; 34(6):485-8. PubMed ID: 16393774
[TBL] [Abstract][Full Text] [Related]
7. Sensory polyneuropathy associated with paclitaxel-eluting coronary stent.
Srinivasan J; Jones HR
J Neurol Sci; 2009 Sep; 284(1-2):175-6. PubMed ID: 19358999
[TBL] [Abstract][Full Text] [Related]
8. Natalizumab: new drug. Multiple sclerosis: risky market approval.
Prescrire Int; 2008 Feb; 17(93):7-10. PubMed ID: 18354844
[TBL] [Abstract][Full Text] [Related]
9. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
10. Steroid-responsive paraneoplastic demyelinating neuropathy and myelopathy associated with breast carcinoma.
Rajabally YA; Qaddoura B; Abbott RJ
J Clin Neuromuscul Dis; 2008 Dec; 10(2):65-9. PubMed ID: 19169093
[TBL] [Abstract][Full Text] [Related]
11. Severe local skin reactions to interferon beta-1b in multiple sclerosis-improvement by deep subcutaneous injection.
Nakamura Y; Kawachi Y; Furuta J; Otsuka F
Eur J Dermatol; 2008; 18(5):579-82. PubMed ID: 18693165
[TBL] [Abstract][Full Text] [Related]
12. [Skin reactions to interferon alpha in a series of 92 patients with multiple sclerosis].
Fortuño Y; Marcoval J; Gallego I; Moreno A; Arbizu T; Peyrí J
Med Clin (Barc); 1999 Oct; 113(12):447-8. PubMed ID: 10570511
[TBL] [Abstract][Full Text] [Related]
13. Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a.
Schwid SR; Decker MD; Lopez-Bresnahan M;
Neurology; 2005 Dec; 65(12):1964-6. PubMed ID: 16380621
[TBL] [Abstract][Full Text] [Related]
14. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
[TBL] [Abstract][Full Text] [Related]
15. Multiple sclerosis: interferon beta for some serious forms.
Prescrire Int; 2007 Dec; 16(92):252-7. PubMed ID: 18092425
[TBL] [Abstract][Full Text] [Related]
16. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.
Gilli F; Valentino P; Caldano M; Granieri L; Capobianco M; Malucchi S; Sala A; Marnetto F; Bertolotto A
Neurology; 2008 Dec; 71(24):1940-7. PubMed ID: 18971450
[TBL] [Abstract][Full Text] [Related]
17. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS.
Sorensen PS; Tscherning T; Mathiesen HK; Langkilde AR; Ross C; Ravnborg M; Bendtzen K
Neurology; 2006 Nov; 67(9):1681-3. PubMed ID: 17101906
[TBL] [Abstract][Full Text] [Related]
20. Chronic myeloid leukaemia in two multiple sclerosis patients on interferon beta-1a.
Almeida L; Neves M; Cardoso E; Melo A
J Clin Pharm Ther; 2009 Feb; 34(1):125-7. PubMed ID: 19125911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
